Although no published data exist on the use of aclidinium during breastfeeding, it produces low maternal serum levels because of rapid hydrolysis to inactive metabolites. The risk to the breastfed infant of maternal aclidinium inhalation is small. Breastfeeding can be continued during aclidinium therapy.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Bendien SA, de Kruif MD, Feitsma H, et al. Summary of the Dutch Multidisciplinary Practice Guideline on Asthma and Pregnancy. J Allergy Clin Immunol Pract 2024;12:1751-62 [PubMed: 38513758]
Substance Identification
Substance Name
Aclidinium
CAS Registry Number
727649-81-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Asthmatic Agents
Parasympatholytics
Muscarinic Antagonists
Bronchodilator Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
